Skip to main content
NCBI home page
Canadian Medical Association Journal logoLink to Canadian Medical Association Journal
. 1980 Sep 6;123(5):365–371.

Combination v. sequential therapy with melphalan, 5-fluorouracil and methotrexate for advanced ovarian cancer.

A B Miller, D J Klaassen, D A Boyes, D J Dodds, A Gerulath, M E Kirk, M Levitt, J G Pearson, C Wall
PMCID: PMC1704783  PMID: 7020903

Abstract

The results of a national clinical trial to compare combination and sequential chemotherapy for stage III or IV ovarian cancer are reported. Of the 253 patients from 16 centres across Canada who were admitted to the trial 13 were excluded from the analysis. All the patients were observed for 2 to 5 years from entry into the trial. There were no differences in response to therapy or in survival between the patients treated with melphalan followed by 5-fluorouracil and then by methotrexate in high dosage and the patients treated with the same agents in combination. Patients with minimal residual disease after resection of stage III ovarian cancer had a good prognosis. Other favourable prognostic factors were age (less than 55 years), performance status (90% or 100% on the Karnofsky scale) and histologic grade of the tumour.

Full text

PDF
365

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ANSFIELD F. J., SCHROEDER J. M., CURRERI A. R. Five years clinical experience with 5-fluorouracil. JAMA. 1962 Jul 28;181:295–299. doi: 10.1001/jama.1962.03050300015003. [DOI] [PubMed] [Google Scholar]
  2. Beck R. E., Boyes D. A. Treatment of 126 cases of advanced ovarian carcinoma with cyclophosphamide. Can Med Assoc J. 1968 Mar 16;98(11):539–541. [PMC free article] [PubMed] [Google Scholar]
  3. Bruckner H. W., Pagano M., Falkson G., Creech R., Arseneau J. C., Horton J., Brodovsky H., Davis T. E., Slayton R. W., Greenspan E. Controlled prospective trial of combination chemotherapy with cyclophosphamide, adriamycin, and 5-fluorouracil for the treatment of advanced ovarian cancer: a preliminary report. Cancer Treat Rep. 1979 Feb;63(2):297–299. [PubMed] [Google Scholar]
  4. Dembo A. J., Bush R. S., Beale F. A., Bean H. A., Pringle J. F., Sturgeon J. F. The Princess Margaret Hospital study of ovarian cancer: stages I, II, and asymptomatic III presentations. Cancer Treat Rep. 1979 Feb;63(2):249–254. [PubMed] [Google Scholar]
  5. Ehrlich C. E., Einhorn L., Williams S. D., Morgan J. Chemotherapy for stage III-IV epithelial ovarian cancer with cis-dichlorodiammineplatinum(II), adriamycin, and cyclophosphamide: a preliminary report. Cancer Treat Rep. 1979 Feb;63(2):281–288. [PubMed] [Google Scholar]
  6. Frick H. C., 2nd, Atchoo N., Adamsons K., Jr, Taylor H. C., Jr The efficacy of chemotherapeutic agents in the management of disseminated gynecologic cancer. Am J Obstet Gynecol. 1965 Dec 15;93(8):1112–1121. doi: 10.1016/0002-9378(65)90181-x. [DOI] [PubMed] [Google Scholar]
  7. Frick H. C., 2nd, Tretter P., Tretter W., Hyman G. A. Disseminated carcinoma of the ovary treated by L-phenylalanine mustard. Cancer. 1968 Mar;21(3):508–513. doi: 10.1002/1097-0142(196803)21:3<508::aid-cncr2820210322>3.0.co;2-r. [DOI] [PubMed] [Google Scholar]
  8. Greenspan E. M. Thio-TEPA and methotrexate chemotherapy of advanced ovarian carcinoma. J Mt Sinai Hosp N Y. 1968 Jan-Feb;35(1):52–67. [PubMed] [Google Scholar]
  9. Hreshchyshyn M. M., Graham J. B. Chemotherapy of ovarian cancer. Int Surg. 1967 Apr;47(4):398–401. [PubMed] [Google Scholar]
  10. Jacobs E. M., Reeves W. J., Jr, Wood D. A., Pugh R., Braunwald J., Bateman J. R. Treatment of cancer with weekly intravenous 5-fluorouracil. Study by the Western Cooperative Cancer Chemotherapy Group (WCCCG). Cancer. 1971 Jun;27(6):1302–1305. doi: 10.1002/1097-0142(197106)27:6<1302::aid-cncr2820270604>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
  11. Klaassen D. J., Boyes D. A., Gerulath A., Levitt M., Miller A. B., Pearson J. G. Preliminary report of a clinical trial of the treatment of patients with advanced stage III and IV ovarian cancer with melphalan, 5-fluorouracil, and methotrexate in combination and sequentially: a study of the Clinical Trials Group of the National Cancer Institute of Canada. Cancer Treat Rep. 1979 Feb;63(2):289–295. [PubMed] [Google Scholar]
  12. LEBHERZ T. B., HUSTON J. W., AUSTIN J. A., BOYCE C. R. SUSTAINED PALLIATION IN OVARIAN CARCINOMA. Obstet Gynecol. 1965 Apr;25:475–478. [PubMed] [Google Scholar]
  13. Levitt M., Mosher M. B., DeConti R. C., Farber L. R., Skeel R. T., Marsh J. C., Mitchell M. S., Papac R. J., Thomas E. D., Bertino J. R. Improved therapeutic index of methotrexate with "leucovorin rescue". Cancer Res. 1973 Jul;33(7):1729–1734. [PubMed] [Google Scholar]
  14. Malkasian G. D., Jr, Decker D. G., Mussey E., Johnson C. E. Observations on gynecologic malignancy treated with 5-fluorouracil. Am J Obstet Gynecol. 1968 Apr;100(7):1012–1017. doi: 10.1016/s0002-9378(15)33764-9. [DOI] [PubMed] [Google Scholar]
  15. Masterson J. G., Nelson J. H., Jr The role of chemotherapy in the treatment of gynecologic malignancy. Am J Obstet Gynecol. 1965 Dec 15;93(8):1102–1111. doi: 10.1016/0002-9378(65)90179-1. [DOI] [PubMed] [Google Scholar]
  16. Moertel C. G., Hanley J. A. The effect of measuring error on the results of therapeutic trials in advanced cancer. Cancer. 1976 Jul;38(1):388–394. doi: 10.1002/1097-0142(197607)38:1<388::aid-cncr2820380156>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]
  17. Parker R. T., Parker C. H., Wilbanks G. D. Cancer of the ovary. Survival studies based upon operative therapy, chemotherapy, and radiotherapy. Am J Obstet Gynecol. 1970 Nov 15;108(6):878–888. [PubMed] [Google Scholar]
  18. Peto R., Pike M. C., Armitage P., Breslow N. E., Cox D. R., Howard S. V., Mantel N., McPherson K., Peto J., Smith P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977 Jan;35(1):1–39. doi: 10.1038/bjc.1977.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Smith J. P., Rutledge F. Chemotherapy in the treatment of cancer of the ovary. Am J Obstet Gynecol. 1970 Jul 1;107(5):691–703. doi: 10.1016/s0002-9378(16)33987-4. [DOI] [PubMed] [Google Scholar]
  20. Sullivan R. D., Miller E., Zurek W. Z., Oberfield R. A., Ojima Y. Re-evaluation of methotrexate as an anticancer drug. Surg Gynecol Obstet. 1967 Oct;125(4):819–824. [PubMed] [Google Scholar]
  21. Vogl S. E., Berenzweig M., Kaplan B. H., Moukhtar M., Bulkin W. The CHAD and HAD regimens in advanced ovarian cancer: combination chemotherapy including cyclophosphamide, hexamethylmelamine, adriamycin, and cis-dichlorodiammineplatinum(II). Cancer Treat Rep. 1979 Feb;63(2):311–317. [PubMed] [Google Scholar]
  22. Wallach R. C., Kabakow B., Blinick G., Antopol W. Thio-tepa chemotherapy for ovarian carcinoma. Influence of remission and toxicity on survival. Obstet Gynecol. 1970 Feb;35(2):278–286. [PubMed] [Google Scholar]
  23. Young R. C., Chabner B. A., Hubbard S. P., Fisher R. I., Bender R. A., Anderson T., Simon R. M., Canellos G. P., DeVita V. T., Jr Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. N Engl J Med. 1978 Dec 7;299(23):1261–1266. doi: 10.1056/NEJM197812072992301. [DOI] [PubMed] [Google Scholar]

Articles from Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES